Thailand "will not end" compulsory licenses

31 August 2008

Thailand's Public Health Minister, Chavarat Charnviakul, has stated his intention to resist attempts by France-based drug major Sanofi-Aventis to have the previous, military-backed government's populist policy of compulsory licensing of cardiovascular and oncology products. The Bangkok Post reported that the French firm had offered to compensate Thailand's Government Pharmaceutical Organization for the added cost of the branded products compared with copy drugs made in India.

The change of government since the restoration of democratic rule has led to the abandoning of new compulsory licenses being issued, a trend which had expanded from antiretrovirals to cover several therapy areas (Marketletters passim). However, despite some indications that the government would like to improve its international reputation for upholding intellectual property rights, significant public opposition has prevented any changes to established compulsory licenses issued in the past three years.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight